By Robert Zott, Director of Advisory Services Development
Originally published March 27, 2018
It’s easy to read Europe’s Clinical Evaluation Guidance Document MEDDEV 2.7/1 Revision 4 (referred to as “Rev. 4”) and come away with the impression that clinical data—whether in the form of investigations carried out by the manufacturer of a medical device or published literature on the subject device or an equivalent—is required in order to meet the guidance.
While clinical data is required for manufacturers of high risk devices and implants, the vast majority of manufacturers that make low-to-medium risk devices may not need to conduct clinical trials for their products or produce peer-reviewed literature that supports their clinical use.
This article helps identify the specific clauses of the guidance document and regulations that pertain to clinical data and explores alternative pathways to compliance.
Access the article here.
The article is free!
Simply fill in the form below, verify your email address
and you’ll be sent a link to download the article.
- The New Post-Market Surveillance Regulations for Europe, Part 2: Serious Incidents Get A Serious Overhaul.71By Robert Zott, Director of Advisory Services Development Originally published November 13, 2018 There is now 1 year, 6 months and 20 days until the application date upon which the new European Medical Device Regulation (MDR) goes into effect. For those charged with the task of upgrading systems for MDR compliance, that’s 567 days or…
- 58By Robert Zott, Director of Advisory Services Development Originally published September 10, 2018 At the time of this writing, there is 1 year, 8 months, and 18 days—that’s 626 days or 15,024 hours—before the new European Medical Device Regulation (MDR) will become the law of the land. For those affected by the tighter scrutiny of…
- The New Post-Market Surveillance Regulations for Europe - Part 3: Trending, Analysis and Documentation56By Robert Zott, Director of Advisory Services Development Originally published February 15, 2019 In this final installment of the new Post-Market Surveillance (PMS) requirements from the forthcoming Medical Device Regulation (MDR), we’ll examine trend reporting (Article 88 of the MDR), the analysis of serious incidents and field safety corrective actions (Article 89), and the technical…